Skip to content

The role of weight reduction on the severity of lower urinary tract symptoms in obese male patients with benign prostatic hyperplasia

The role of weight reduction on the severity of lower urinary tract symptoms in obese male patients with benign prostatic hyperplasia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12001978
Enrollment
Unknown
Registered
2012-03-02
Start date
2012-01-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperphasia

Interventions

A:Weight reduction program supervised by physician, dietitian and physiotherapist for 48 weeks.
B:Weight reduction advice for 48 weeks

Sponsors

Urology Division, Department of Surgery, CUHK
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male patient with aged >=50 years old; 2. Defined as obese, with BMI > 25 Kg/m2l; 3. With moderate to severe lower urinary tract symptom (IPSS >7); 4. Maximum flow rate between 5 – 15 ml/s; 5. Post-void residual urine 30 cc.

Exclusion criteria

Exclusion criteria: 1. Patients considered as extreme obese, with BMI >35 Kg/m2; 2. Patients with LUTS due to urethral stricture, neurogenic bladder or other structural abnormality; 3. Patients with long-term catheterization or who perform intermittent self-catheterization ? Patients with known history of prostate cancer or bladder cancer at the time of assessment; 4. Patients with on 5a-reductase inhibitors, phytotherapy, or other hormonal therapy; 5. Patients with history of prostatic / bladder surgery or other pelvic surgery that may affect voiding; 6. Patients with bladder stones or an active urinary tract infection at the time of assessment; 7. Patient do not tolerate tamsulosin OCAS for the management of LUTS; 8. Patient with poor cardiac status (NYHA class III or above) or other medical conditions that are not suitable for intense exercise or weight reduction programme.

Design outcomes

Primary

MeasureTime frame
Change in total score of International Prostate Symptom Score (IPSS) at the end of trial (52 weeks),;maximum flow rate (Qmax);total irritative symptom score of IPSS (Q2, 4 & 7);number of nocturia;QoL score;PSA level;prostate volume;

Countries

China

Contacts

Public ContactProf. Ng, Chi Fai
ngcf@surgery.cuhk.edu.hk+852 26322625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026